APPLIED PHARMACEUTICAL TOXICOLOGY 2020 - meeting cancelled

After careful consideration of the ongoing spread of COVID-19 (coronavirus)  The Boston Society Board of Directors decided not to conduct APT 2020 Annual Meeting @ Takeda, Cambridge this month (May 12-14, 2020).


Save the Date for 2021!

May 11 - 13, 2021
Genentech, South San Francisco, CA

 

Plenary Speakers for 2020

 

Jeffrey Gotts, MD, PhD

Assistant Professor, Department of Medicine, UCSF

Chasing the Cloud or Choking on it: The Pulmonary Toxicity of E-Cigarettes

     
 

Daniel Nomura, PhD

Professor of Chemical Biology, University of California at Berkeley

Reimagining Druggability using Chemoproteomic Platforms

     
 

Lisa Plitnick, PhD

Senior Research Scientist, Merck

Discovery and Development of Vaccines and Worldwide Regulatory Experience

     

 

 Speakers Confirmed for 2020

 

Christopher Aluise, PhD

Senior Research Scientist, Toxicology, Eli Lilly and Company

Title TBA

Rogley Boyce, DVM, PhD, DAVCP

Consultant - Nonclinical Lead for Evenity, Amgen

Nonclinical Cardiovascular Safety Evaluation of Romosozumab-aqqg

     

   
 

Christopher Brynczka, PhD, DABT

Senior Principal Scientist, Merck

Title TBA

 

Paola Costaldi, PhD

Associate Director, Head of Chemical Biology, AstraZeneca

Title TBA

     

   
   

Brian Enright, PhD, DABT

Senior Principal Scientist, Preclinical Safety, AbbVie

Utility of Juvenile Animal Studies for Antibody-Drug Conjugates

Juliane Gust, MD, PhD

Center for Integrative Brain Research, Seattle Children's Hospital

CAR T Neurotoxicity: Translational Insights

     

   
 

Tracy Henriques, PhD, DABT

Toxicologist, AbbVie

Preclinical to Clinical Translation of ADA: Putting Data to the Dogma

Cris Kamperschroer, PhD

Senior Principal Scientist, Pfizer

Nonclinical Evaluation of CD3 Bispecific Molecules

     

   
    Lucas Kempf, MD

Medical Officer, Rare Diseases Program, FDA

Regulatory Challenges of Rare disease Drug Development

 

Hervé Lebrec, PharmD, PhD, DABT

Scientific Director, Translational Safety & Bioanalytical Services, Amgen

Experience with Nonhuman Primate Models in CAR-T Therapy Nonclinical Safety Assessment

     

   
 

Lisa Mangus, DVM, PhD, DACVP

Assistant Professor, Dept. of Molecular & Comparative Pathobiology, Johns Hopkins School of Medicine

Intra-Epidermal Nerve Fiber Analysis: a Sensitive, Clinically-Relevant Tool for Assessing Sensory Nerve Damage in Animal Models

Kim Maratea, DVM, PhD, DACVP

Associate Director Pathology, Oncology Safety, AstraZeneca

Early Assessment of Bone Marrow Toxicity in Immunodeficient Mice

     

   
   

John McNulty, PhD

Director, Shire/Takeda

Nonclinical Safety Considerations in the Development of Treatments for Rare Diseases at Shire

Scott Mittelstadt, PhD

Director of Investigative Toxicology and Safety Pharmacology, AbbVie

CiPA: Practical Applications in Discovery

     

   
 

Suman Mukherjee, PhD

Director, In Vivo PK and TK Group, Safety Assessment, Merck

The Impact of Toxicokinetics on the Design and Interpretation of Toxicology Studies

Kara Pearson, PhD

Director, Analytical and Biochemical Toxicology, Merck

Using Stable Isotope Labeled Tracers to Illuminate Aspects of Hepatic Function and Provide a Translational Biomarker of BSEP Inhibition

     

   
 

Michael Polydefkis, MD MHS

Professor, Neurology, Johns Hopkins University School of Medicine

TBA

Mohan Rao, PhD

Computational Toxicologist/Biologist, AbbVie

Tntegrating Cheminformatics and Off-Target Safety Assessments to Predict Testicular Toxicity

     

   
 

Chandra Saravanan, PhD

Senior Veterinary Pathologist, Novartis Institutes for BioMedical Research

Title TBA

Nicola Stagg, PhD, DABT

Senior Scientist/Toxicologist, Genentech

Title TBA

     

   
   

Jonathan Stauber, PhD

Director, ImaBiotech

Role of Drug Exposure Quantification for Safety and Efficacy Evaluation in Non Clinical and Clinical Trials 

 

Jessica Sutherland, PhD, DABT

Senior Director, Toxicology, Alnylam Pharmaceuticals

The Nonclinical Safety Profile of ONPATTRO® (patisiran), a First-in Class RNAi Therapeutic for the Treatment of Polyneuropathy of Hereditary Transthyretin-mediated Amyloidosis (hATTR amyloidosis)

     

   
   

Larry Whiteley, DVM

Senior Director, Pfizer

Title TBA

Francis Wolenski, PhD, DABT

Senior Toxicologist, Drug Safety Research & Evaluation, Takeda

Navigating a Tough Regulatory Interaction – Is this Phase 1 or 2? 


Sessions for the 2020 Discovery Toxicology Workshop

Session I:  IO in Discovery Toxicology Space

Session II:  Novel Approaches to Identify Off-Target Drivers of Toxicity

Session III:  Case Studies in Investigative Toxicology

 

Sessions for the 2020 Development Toxicology Workshop

Session IV:  Regulatory Hurdles

Session V:  Developing Products for Rare Diseases and Conditions

Session VI:  Non-Clinical to Clinical Translation - Case Studies

Session VII:  Peripheral Neuropathy

 

 

Download APT 2019 Program Guide  

 

 


Join our LinkedIn Group

Workshops

Discovery

Development

Registration

Click here to register for the APT 2020 conference online.

APT 2020 will take place

May 12-14, 2020 at:

Takeda

Cambridge, MA

 

The Boston Society

The Boston Society (R) is an internationally-recognized NON-PROFIT organization dedicated to bringing the best scientific ideas to industrial practice through focused, timely workshops and conferences. 501(c)3

Updates

Sign Up Today!

Privacy Policy